Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has earned an average rating of “Hold” from the nine analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.00.

BCYC has been the topic of several research reports. Citizens Jmp dropped their target price on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a report on Wednesday, March 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, April 10th. Royal Bank Of Canada dropped their target price on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 18th. Citigroup restated a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $12.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, April 30th.

Bicycle Therapeutics Trading Up 1.3%

Shares of BCYC stock opened at $4.01 on Friday. Bicycle Therapeutics has a 12-month low of $3.92 and a 12-month high of $9.18. The firm’s 50 day moving average is $4.52 and its 200 day moving average is $5.43. The stock has a market capitalization of $279.94 million, a P/E ratio of -1.27 and a beta of 1.54.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.25). Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%.The company had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $7.50 million. As a group, equities analysts predict that Bicycle Therapeutics will post -1.97 earnings per share for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 5,967 shares of Bicycle Therapeutics stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total transaction of $29,297.97. Following the transaction, the chief executive officer owned 613,029 shares in the company, valued at $3,009,972.39. This trade represents a 0.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 9,992 shares of company stock worth $49,363. Company insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Assetmark Inc. boosted its stake in shares of Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after acquiring an additional 1,552 shares during the last quarter. Man Group plc raised its position in shares of Bicycle Therapeutics by 4.8% during the 4th quarter. Man Group plc now owns 42,860 shares of the company’s stock valued at $303,000 after purchasing an additional 1,969 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Bicycle Therapeutics by 1.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock valued at $976,000 after purchasing an additional 2,243 shares during the period. Flax Pond Capital LLC raised its position in shares of Bicycle Therapeutics by 1.4% during the 1st quarter. Flax Pond Capital LLC now owns 176,136 shares of the company’s stock valued at $817,000 after purchasing an additional 2,503 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of Bicycle Therapeutics by 21.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock valued at $116,000 after purchasing an additional 2,668 shares during the period. Hedge funds and other institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.